AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Conceptual business illustration of upcoming business problem metaphor with falling domino and businessman silhouette. Minimalistic vector eps 10 illustration

ALS

HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from which have largely mirrored the dismal success rate in ALS overall.

January 10, 2025

5 min read

Heather McKenzie

Pictured: Office building science collage

Career Advice

The Top 12 Companies Hiring in Biopharma Now

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

January 9, 2025

1 min read

Angela Gabriel

Collage showing hands holding a light bulb

Career Advice

Computational Biology, Data Science Hot Areas for Oncology R&D Hiring

As market values increase for computational biology and data science, biopharma companies are looking to hire R&D professionals in those areas. A biotech talent acquisition expert shares his insights on these in-demand roles.

January 2, 2025

5 min read

Angela Gabriel

Update: AbbVie headquarters building in California

Mergers & acquisitions

AbbVie Continues Deal-Making Spree With $200M Nimble Buy

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and cement its long-term growth prospects following the Phase II failure of emraclidine in schizophrenia and in anticipation of market erosion for Skyrizi and Rinvoq, according to Guggenheim Partners analysts.

December 16, 2024

2 min read

Tristan Manalac

Balloon and missed bow spears arround . Target audience and marketing concept . This is a 3d render illustration .

Neuroscience

5 Clinical Assets That Flopped in 2024

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five clinical trial flops that stole headlines over the past 12 months.

December 16, 2024

6 min read

Heather McKenzie

Podcast

Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment model; Eli Lilly and Novo Nordisk pump new funds into manufacturing; and AbbVie makes a Cerevel comeback while uniQure clears a path toward accelerated approval in Huntington’s disease.

December 11, 2024

1 min read

Heather McKenzie

Collage with halftone hand, light bulb and head. Creative idea generation or brainstorm concept vector pop art retro style illustration. Design element for infographic, poster, website

Parkinson’s disease

A Month After Stunning Schizophrenia Fail, AbbVie’s Other Cerevel Asset Shines Again

Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie announced the Phase II failure of another key Cerevel asset, emraclidine.

December 9, 2024

1 min read

Annalee Armstrong

Illustration showing woman in hybrid workplace sharing her time between an office and working from home remotely

Job Trends

Flexing on the Competition? Smaller Companies Get Higher Marks for Flexibility

Many biopharma professionals view smaller companies as having the best flexibility and remote work options, but that doesn’t mean their larger counterparts are failing in that area. Several professionals, including Apogee Therapeutics and Insmed executives, share their insights.

November 21, 2024

6 min read

Angela Gabriel